{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2BSOC", "query": { "intervention": "Placebo+SOC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 203, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2BSOC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T21:32:47.480Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06264310", "title": "To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure", "Worsening Heart Failure (WHF)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "R2R01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "River 2 Renal Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-03-01", "completion_date": "2024-11-25", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 8, "location_summary": "Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Inverness", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264310" }, { "nct_id": "NCT05497284", "title": "To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "LTP001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "40 Years to 100 Years" }, "enrollment_count": 46, "start_date": "2022-11-10", "completion_date": "2024-09-26", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Kansas City, Kansas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05497284" }, { "nct_id": "NCT04391309", "title": "COVID-19 and Anti-CD14 Treatment Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)", "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" ], "interventions": [ { "name": "anti-CD14", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "remdesivir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2021-04-12", "completion_date": "2022-02-04", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 5, "location_summary": "Sarasota, Florida • Seattle, Washington", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391309" }, { "nct_id": "NCT07349771", "title": "Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Axatilimab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Skin Biopsy", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-06-01", "completion_date": "2033-06-01", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349771" }, { "nct_id": "NCT04619706", "title": "Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "FSD201", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care for Covid-19", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Quantum Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2020-12-14", "completion_date": "2021-08-24", "has_results": false, "last_update_posted_date": "2022-12-05", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 10, "location_summary": "Miami, Florida • St. Petersburg, Florida • Idaho Falls, Idaho + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Winfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04619706" }, { "nct_id": "NCT03830866", "title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Cervical Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "external beam radiation therapy (EBRT) + brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 770, "start_date": "2019-02-15", "completion_date": "2023-07-03", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 16, "location_summary": "Phoenix, Arizona • La Jolla, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03830866" }, { "nct_id": "NCT05419011", "title": "Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Colorectal Neoplasm", "Lynch Syndrome" ], "interventions": [ { "name": "Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Nogapendekin Alfa", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2023-05-08", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419011" }, { "nct_id": "NCT01086540", "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-Associated PAH" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "CMRI", "type": "DIAGNOSTIC_TEST" }, { "name": "prednisone", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2011-06-24", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 17, "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086540" }, { "nct_id": "NCT04375397", "title": "Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CoronaVirus Induced Disease-2019 (COVID-19)" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-06-06", "completion_date": "2021-06-08", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 9, "location_summary": "Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375397" }, { "nct_id": "NCT05306574", "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Telitacicept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vor Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 91, "start_date": "2022-06-20", "completion_date": "2025-01-06", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-09-16T21:32:47.480Z", "location_count": 12, "location_summary": "Anniston, Alabama • Mission Hills, California • Orange, California + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306574" } ] }